An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

Model scores of the 29,894 trials active now.

Model score 52% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (734 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2010-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: alzheimerlong termterm safetythe longtolerability
  Phrases that lowered it: patientspatientpreviousresultsopen label
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 16.0% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 361 (raises risk) · Sponsor's track record
• Sponsor's past trials: 626 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Phase: 3 (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 0 (raises risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design
• Minimum age: 50 (lowers risk) · Who can join
• Keywords listed: 0 (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease NCT01066546 · started 2010 · scored riskier than 99% of active trials terminated
• A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease NCT00838110 · started 2009 · scored riskier than 67% of active trials completed
• Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease NCT00704782 · started 2008 · scored riskier than 67% of active trials terminated
• Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil NCT00829816 · started 2008 · scored riskier than 19% of active trials completed
• An Extension of the CONCERT Protocol (DIM18) NCT01152216 · started 2010 · scored riskier than 66% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.